Heterologous Prime-Boost Oral Immunization with GK-1 Peptide from Taenia crassicepsCysticerci Induces Protective Immunity

التفاصيل البيبلوغرافية
العنوان: Heterologous Prime-Boost Oral Immunization with GK-1 Peptide from Taenia crassicepsCysticerci Induces Protective Immunity
المؤلفون: Fragoso, Gladis, Esquivel-Guadarrama, Fernando, Santana, M. Angélica, Bobes, Raul J., Hernández, Beatriz, Cervantes, Jacquelynne, Segura, René, Goldbaum, Fernando A., Sciutto, Edda, Rosas, Gabriela
المصدر: Clinical and Vaccine Immunology (formerly CDLI); May 2011, Vol. 18 Issue: 7 p1067-1076, 10p
مستخلص: ABSTRACTOral immunization is a goal in vaccine development, particularly for pathogens that enter the host through the mucosal system. This study was designed to explore the immunogenic properties of the Taenia crassicepsprotective peptide GK-1 administered orally. Mice were orally immunized with the synthetic GK-1 peptide in its linear form with or without the Brucellalumazine synthase (BLS) protein adjuvant or as a chimera recombinantly bound to BLS (BLS-GK-1). Mice were boosted twice with GK-1 only at 15-day intervals. A significant rate of protection of 64.7% was achieved in GK-1-immunized mice, and that rate significantly increased to 91.8 and 96% when mice were primed with GK-1 coadministered with BLS as an adjuvant and BLS as a carrier, respectively. Specific antibodies and T cell activation and proliferation accompanied the protection induced, revealing the potent immunogenicity of GK-1. Through immunohistochemical studies, GK-1 was detected in T and B cell zones of the Peyer's patches (PP) and mesenteric lymph nodes. In the latter, abundant proliferating cells were detected by 5'-bromo-2'-deoxyuridine incorporation. No proliferation was detected in PP. Altogether, these results portray the potent immunogenic properties of GK-1 administered orally and reinforce the usefulness of BLS as an adjuvant and adequate vaccine delivery system for oral vaccines.
قاعدة البيانات: Supplemental Index
الوصف
تدمد:15566811
1556679X
DOI:10.1128/CVI.05030-11